Last reviewed · How we verify
Shade Uvaguard (AVOBENZONE)
Shade Uvaguard works by absorbing and scattering UV radiation to prevent skin damage.
Shade Uvaguard (avobenzone) is a small molecule drug developed by BAYER HEALTHCARE LLC, targeting tyrosinase. It is an FDA-approved avobenzone drug class, initially approved in 1992. Shade Uvaguard is used to treat various skin conditions, but specific indications are not provided. The commercial status of Shade Uvaguard is owned by BAYER HEALTHCARE LLC, with unknown generic manufacturers and patent status. Key safety considerations are not specified.
At a glance
| Generic name | AVOBENZONE |
|---|---|
| Sponsor | Bayer |
| Drug class | avobenzone |
| Target | Tyrosinase |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
| First approval | 1992 |
Mechanism of action
Active ingredients PurposeAvobenzone 2%.............................................................................SunscreenHomosalate 10%............................................................................SunscreenOctisalate 5%.................................................................................SunscreenOxybenzone 3%.............................................................................Sunscreen.
Approved indications
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Fatigue
- Headache
- Dizziness
- Insomnia
- Anxiety
- Depression
- Suicidal ideation
- Suicidal behavior
Key clinical trials
- Singlet Oxygen Quantification After Skin Exposure to Ultraviolet A (UVA) Light (NA)
- Assessing a Natural Product Plus Bioadhesive Nanoparticle (BNP) Sunscreen (PHASE1)
- Assessment of the Human Systemic Absorption of Sunscreen Ingredients (PHASE1)
- Determination of Sun Protection in Sunscreen Formulas (Study SR09-15)(P08236)(COMPLETED) (PHASE3)
- Ultraviolet and UV-Visible Light Photoprotection for the Treatment of Melasma (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Shade Uvaguard CI brief — competitive landscape report
- Shade Uvaguard updates RSS · CI watch RSS
- Bayer portfolio CI